HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Abstract
In an examination of the relationships among plasma aminoglycoside concentrations, the minimal inhibitory concentration (MIC) for the infecting organism, and therapeutic outcome, data were analyzed from 236 patients with gram-negative bacterial infections who were participants in four clinical trials of gentamicin, tobramycin, and amikacin. Clinical response to therapy occurred in 188 (80%) patients. Elevated maximal and mean peak aminoglycoside concentration/MIC ratios were strongly associated with clinical response (P less than .00001 and P less than .0001, respectively). A graded dose-response effect was found between an increasing maximal peak concentration/MIC ratio and clinical response. By logistic regression the peak concentration/MIC ratios were associated significantly with clinical response after adjustment for underlying severity of illness and other factors correlated with response. These results demonstrate that a high peak concentration relative to the MIC for the infecting organism is a major determinant of the clinical response to aminoglycoside therapy.
AuthorsR D Moore, P S Lietman, C R Smith
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 155 Issue 1 Pg. 93-9 (Jan 1987) ISSN: 0022-1899 [Print] United States
PMID3540140 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Gentamicins
  • Amikacin
  • Tobramycin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amikacin (blood, pharmacology, therapeutic use)
  • Bacterial Infections (drug therapy, microbiology)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Gentamicins (blood, pharmacology, therapeutic use)
  • Gram-Negative Bacteria (drug effects, isolation & purification)
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Random Allocation
  • Tobramycin (blood, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: